Driven by rising rates of injection drug use, the incidence of hepatitis C (HCV) in the U.S. has tripled in the last five years. The amfAR policy office advocates for increased access to prevention and treatment services for people living with, or at risk for, HCV, and maintains a database of epidemiologic, policy, and funding data on opioid use, HIV, and HCV.